Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer’s Disease
Eisai (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) announced today that the Australian Therapeutic Goods...
Company
XtalPi and Bio‑Sincerity Announce AI‑Robotics R&D Partnership
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Hangzhou Bio‑Sincerity (SHE: 301096) today...
Fosun Kairos Secures NMPA Approval for Second CAR‑T Product, FKC889, Targeting Relapsed/Refractory B‑Cell ALL
Fosun Kairos, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196),...
FibroGen Launches Phase 2 Dose‑Optimization Trial for CD46‑Targeted ADC FG‑3246 in Metastatic Castration‑Resistant Prostate Cancer
FibroGen, Inc. (NASDAQ: FGEN) announced today the start of a randomized, open‑label Phase 2 monotherapy trial...
Trump Administration Expands Section 232 Tariffs on Robotics, Industrial Machinery and Medical Devices
President Donald J. Trump’s administration has opened new investigations under Section 232 of the Trade Expansion Act, targeting...
Hengrui Pharma & Glenmark Partner on Trastuzumab Rezecan ADC for HER2‑Positive Lung Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced an exclusive licensing agreement with Glenmark...
Jiangsu Hengrui Receives NMPA Acceptance for SHR7280 Oral GnRH Antagonist
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products...
Johnson & Johnson Announces International Withdrawal of Linx Reflux System
US giant Johnson & Johnson (J&J, NYSE: JNJ) disclosed that it will cease sales of...
RM Bio‑Tech Secures CDE Approval for HF001 Stem‑Cell Therapy in Type 2 Diabetes
Beijing RM Bio‑Tech Co., Ltd. announced that the Center for Drug Evaluation (CDE) under the...
Jiangsu Hengrui’s Adebrelimab New Indication Accepted by NMPA for Stage II‑IIIB NSCLC
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the National Medical Products...
Yantai Dongcheng Secures NMPA Approval for 225Ac‑LNC1011 Alpha‑Particle Radiopharmaceutical to Target Prostate Cancer
China‑based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) announced that its investigational 225Ac‑LNC1011 injection...
Eli Lilly Announces $6.5 B Houston Facility to Boost Synthetic‑Medicine API Production
Eli Lilly (NYSE: LLY) announced today that it will construct a new $6.5 billion manufacturing complex...
Sino Biopharmaceutical Reports First‑Patient Enrollment for LM‑2417 Phase I Trial
China‑based Sino Biopharmaceutical (HKG: 1177) announced today that its internally‑developed Class 1 innovative drug LM‑2417 has...
MSD Teams with Variational AI in $349 Million Generative‑AI Drug Discovery Deal
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has struck a $349 million partnership with Canada‑based...
ProBio and Immunofoco Forge Global CGT Manufacturing Alliance
ProBio, a subsidiary of GenScript Biotech Corporation (HKG: 1548), and China‑based Immunofoco have inked a...
Stealth BioTherapeutics Receives FDA Accelerated Approval for Forzinity in Barth Syndrome
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Stealth BioTherapeutics’ Forzinity (elamipretide)...
Genrix Bio Secures Exclusive Deal for Vecantoxatug and Silevimig with CMS
China‑based Chongqing Genrix Bio Pharmaceutical Co., Ltd. (SHA: 688443) and China Medical System Holdings Ltd....
Roche’s SC Lunsumio Gains CHMP Recommendation for Relapsed Follicular Lymphoma
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the European Medicines Agency’s Committee for Medicinal Products...
Roche’s giredestrant Yields Positive PFS Results in evERA Phase III Study
Roche (SWX: ROG, OTCMKTS: RHHBY) announced that its Phase III evERA trial has met both co‑primary...
Eisai Secures FDA Fast Track for Etalanetug, a Tau Antibody Targeting MTBR
Eisai Co. Ltd. (TYO: 4523) announced today that its investigational tau‑protein antibody etalanetug (E2814) has...